StockNews.AI
LCTX
StockNews.AI
162 days

Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

1. LCTX reports progress in developing allogeneic cell therapies in 2024. 2. Fourth quarter and full year 2024 results to be discussed in a conference call.

Earnings
+0.38%Current Return
VS
-0.84%S&P 500
$0.530903/10 04:07 PM EDTEvent Start
$0.532903/11 10:53 PM EDTLatest Updated
2m saved
Insight
Article

FAQ

Why Bullish?

LCTX's advancement in therapies indicates potential revenue growth, enhancing investor confidence, similar to past biotech advancements leading to stock surges.

How important is it?

Positive financial results or updates can significantly influence investor perception and stock value for LCTX.

Why Short Term?

The immediate announcement of financial results and a business update can create short-term stock price movements.

Related Companies

CRISAVCOONCE
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological conditions, today reported its fourth quarter and full year 2024 financial and operating results and will host a conference call today at 4:30 p.m. Eastern Time to discuss these results and provide a business update. “Throughout 2024, we made substantial progress across multiple fronts, advancing o.

Related News